查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1417537

标靶化微脂体给药市场报告：2030 年趋势、预测与竞争分析

Targeted Liposomes Drug Delivery Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

微脂体标靶化给药的趋势与预测

预计到 2030 年，全球标靶化微脂体给药市场将达到 41 亿美元，2024 年至 2030 年复合年增长率为 8.6%。该市场的主要驱动力是癌症和真菌相关感染疾病等慢性疾病盛行率的上升、对体内药物代谢和吸收过程的了解和认识的提高以及新型治疗方法采用率的提高。全球标靶化微脂体给药市场的未来前景广阔，真菌感染疾病治疗和癌症治疗市场充满机会。

标靶化微脂体给药市场洞察

Lucintel 预测，由于癌症发生率上升，微脂体阿霉素将在预测期内达到最高成长。

由于其高癌症发病率和先进的医疗设施，北美在预测期内将继续成为最大的市场。

常问问题

Q1.市场规模有多大？

A1. 至2030年，全球标靶化微脂体给药市场预计将达到41亿美元。

Q2.市场成长预测如何？

A2. 2024年至2030年，全球标靶化微脂体年增长率成长。

Q3.影响市场成长的主要驱动因素有哪些？

A3. 该市场的主要驱动力是包括癌症和真菌相关感染疾病在内的慢性疾病患病率的上升、对人体药物代谢和吸收过程的了解和认识的提高以及新型治疗方法采用率的提高。

Q4.市场的主要细分市场是什么？

A4. 全球标靶化微脂体给药市场前景广阔，真菌感染疾病治疗和癌症治疗市场充满机会。

Q5. 市场上主要企业有哪些？

A5. 主要标靶化微脂体给药公司如下。

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Q6.未来最大的细分市场是什么？

A6.Lucintel 预测，由于癌症发生率上升，微脂体阿霉素将在预测期内呈现最高增长。

Q7. 未来五年预计哪个地区将成为最大的市场？

A7. 由于癌症发生率高且医疗设施先进，北美在预测期内仍将是最大的市场。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球标靶化微脂体给药市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球标靶化微脂体给药市场趋势（2018-2023）与预测（2024-2030）
  • 按类型分類的全球标靶化微脂体药物递送市场
    • 微脂体体阿霉素
    • 脂质体微脂体
    • 微脂体Amphotericin B
    • 其他的
  • 全球标靶化微脂体药物递送市场（按应用）
    • 真菌感染疾病的治疗
    • 癌症治疗
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 全球标靶化微脂体给药市场（按地区）
  • 北美标靶化微脂体给药市场
  • 欧洲标靶化微脂体给药市场
  • 亚太地区标靶化微脂体给药市场
  • 其他地区标靶化微脂体给药市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型分類的全球标靶化微脂体给药市场成长机会
    • 全球标靶化微脂体给药市场成长机会（按应用）
    • 全球标靶化微脂体给药市场按地区成长机会
  • 全球标靶化微脂体给药市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球标靶化微脂体给药市场产能扩张
    • 全球标靶化微脂体给药市场的合併、收购与合资
    • 认证和许可

第七章主要企业概况

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm
简介目录

Targeted Liposomes Drug Delivery Trends and Forecast

The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets. The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

A more than 150-page report is developed to help in your business decisions.

Targeted Liposomes Drug Delivery by Segment

The study includes a forecast for the global targeted liposomes drug delivery by type, application, and region.

Targeted Liposomes Drug Delivery Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B
  • Others

Targeted Liposomes Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Fungal Infection Therapy
  • Cancer Therapy
  • Others

Targeted Liposomes Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Targeted Liposomes Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted liposomes drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted liposomes drug delivery companies profiled in this report include-

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Targeted Liposomes Drug Delivery Market Insights

Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Features of the Global Targeted Liposomes Drug Delivery Market

Market Size Estimates: Targeted liposomes drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Targeted liposomes drug delivery market size by type, application, and region in terms of value ($B).

Regional Analysis: Targeted liposomes drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted liposomes drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted liposomes drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the targeted liposomes drug delivery market size?

Answer: The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030.

Q2. What is the growth forecast for targeted liposomes drug delivery market?

Answer: The global targeted liposomes drug delivery market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the targeted liposomes drug delivery market?

Answer: The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

Q4. What are the major segments for targeted liposomes drug delivery market?

Answer: The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets.

Q5. Who are the key targeted liposomes drug delivery market companies?

Answer: Some of the key targeted liposomes drug delivery companies are as follows.

  • Catalent
  • Pacira Pharmaceuticals
  • Baxter
  • Lonza
  • Evonik
  • Merck
  • Fareva
  • Vetter
  • Polymun Scientific Immunbiologische Forschung
  • Recipharm

Q6. Which targeted liposomes drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

Q7. In targeted liposomes drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the targeted liposomes drug delivery market by type (liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others), application (fungal infection therapy , cancer therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Targeted Liposomes Drug Delivery Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Targeted Liposomes Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Targeted Liposomes Drug Delivery Market by Type
    • 3.3.1: Liposomal Doxorubicin
    • 3.3.2: Liposomal Paclitaxel
    • 3.3.3: Liposomal Amphotericin B
    • 3.3.4: others
  • 3.4: Global Targeted Liposomes Drug Delivery Market by Application
    • 3.4.1: Fungal Infection Therapy
    • 3.4.2: Cancer Therapy
    • 3.4.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Targeted Liposomes Drug Delivery Market by Region
  • 4.2: North American Targeted Liposomes Drug Delivery Market
    • 4.2.2: North American Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.3: European Targeted Liposomes Drug Delivery Market
    • 4.3.1: European Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.3.2: European Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.4: APAC Targeted Liposomes Drug Delivery Market
    • 4.4.1: APAC Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.4.2: APAC Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
  • 4.5: ROW Targeted Liposomes Drug Delivery Market
    • 4.5.1: ROW Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
    • 4.5.2: ROW Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Type
    • 6.1.2: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Application
    • 6.1.3: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Region
  • 6.2: Emerging Trends in the Global Targeted Liposomes Drug Delivery Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Targeted Liposomes Drug Delivery Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Targeted Liposomes Drug Delivery Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Catalent
  • 7.2: Pacira Pharmaceuticals
  • 7.3: Baxter
  • 7.4: Lonza
  • 7.5: Evonik
  • 7.6: Merck
  • 7.7: Fareva
  • 7.8: Vetter
  • 7.9: Polymun Scientific Immunbiologische Forschung
  • 7.10: Recipharm